{
 "ticker": "PBE",
 "name": "Invesco Biotechnology & Genome ETF",
 "issuer": "Invesco",
 "desk": "themes",
 "url": "https://etfiq.com/funds/PBE",
 "html": "https://etfiq.com/funds/PBE",
 "markdown": "https://etfiq.com/funds/PBE.md",
 "as_of": "2026-09-11",
 "verdict": "PBE holds 32 stocks, and 70% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "30.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBE, already in the S&P 500: 30.1%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBE, active share vs the S&P 500: 99.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "45.9%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBE, top ten holdings: 45.9%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+32.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBE, total return, 1 year: +32.5%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$247m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "PBE, net assets: $247m (SEC filing, whole fund, as filed for Apr 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.59%",
   "source": "485BPOS XBRL, Aug 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "PBE, expense ratio: 0.59% (485BPOS XBRL, Aug 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Jan 4, 2010",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "30.1%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "19.7%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.7%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "45.9%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "32",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 10, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Biogen Inc 5.2%, Gilead Sciences Inc 5.2%, Natera Inc 5.1%, Regeneron Pharmaceuticals Inc 5.0%, Royalty Pharma PLC 5.0%, Vertex Pharmaceuticals Inc 4.9%, Illumina Inc 4.7%, Amgen Inc 4.6%, Sarepta Therapeutics Inc 3.1%, Neurocrine Biosciences Inc 3.0%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$247m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22125.9%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.59%",
   "source": "485BPOS XBRL, Aug 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.60%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "FBT 52%, BBH 43%, IBBQ 38%, BBP 34%, GNOM 29%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+11.5%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+8.2 pts",
   "Gap to Nasdaq-100": "+12.3 pts"
  },
  {
   "window": "6 months",
   "Total return": "+23.3%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+7.2 pts",
   "Gap to Nasdaq-100": "+2.6 pts"
  },
  {
   "window": "1 year",
   "Total return": "+32.5%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+15.0 pts",
   "Gap to Nasdaq-100": "+9.6 pts"
  },
  {
   "window": "3 years",
   "Total return": "+56.6%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221221.2 pts",
   "Gap to Nasdaq-100": "\u221238.4 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+479.9%",
   "S&P 500": "+804.4%",
   "Gap to S&P 500": "\u2212324.5 pts",
   "Gap to Nasdaq-100": "\u22121194.0 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of PBE is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 10, 2026, 30% of PBE by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does PBE hold?",
   "a": "32 positions as published by its issuer for Sep 10, 2026, with the top ten at 46% of the fund. The largest are Biogen Inc at 5.2%, Gilead Sciences Inc at 5.2%, Natera Inc at 5.1%."
  },
  {
   "q": "Has PBE beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 PBE returned +32.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 15.0 points."
  },
  {
   "q": "What does PBE cost?",
   "a": "The prospectus expense ratio is 0.59% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.60%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}